Singapore, Jan. 21 -- GSK plc and Shionogi & Co. have reached an agreement together with Pfizer Inc. for the 11.7% economic interest in UK-based ViiV Healthcare Limited, currently held by Pfizer to be replaced with an investment by Japan-based pharma firm Shionogi.

As a result of this transaction, Shionogi will increase its economic interest in ViiV Healthcare to 21.7%. GSK will maintain its 78.3% majority owned economic interest. Shionogi will continue to have one Director position on the ViiV Healthcare Board, and will be represented by Dr John Keller who has been a Director of ViiV Healthcare since 2012.

Published by HT Digital Content Services with permission from BioSpectrum Asia....